Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VAMSI KOTA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1790902393
CMS profile
172817
Location
AUGUSTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$17,073.30

19 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $14,520.00 3
Travel and Lodging $1,903.43 4
Food and Beverage $649.87 12

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
SERVIER PHARMACEUTICALS LLC $8,051.26 6
Kite Pharma, Inc. $5,990.55 7
NOVARTIS PHARMACEUTICALS CORPORATION $2,906.60 4
Apellis Pharmaceuticals, Inc. $124.89 2

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VAMSI KOTA

NPI 1790902393 · CMS profile ID 172817

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

AUGUSTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790902393?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VAMSI KOTA, NPI 1790902393, CMS profile ID 172817. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790902393?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). VAMSI KOTA, NPI 1790902393, CMS profile ID 172817. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790902393?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
VAMSI KOTA, NPI 1790902393, CMS profile ID 172817, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1790902393?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

19 matching records · $17,073.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 19 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–19 of 19.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $98.4210/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992178012 CMS
SERVIER PHARMACEUTICALS LLC $6,800.0007/16/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055094975 CMS
SERVIER PHARMACEUTICALS LLC $30.0006/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055094955 CMS
SERVIER PHARMACEUTICALS LLC $55.0006/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055094959 CMS
SERVIER PHARMACEUTICALS LLC $15.0006/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055094969 CMS
SERVIER PHARMACEUTICALS LLC $839.8906/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055094949 CMS
SERVIER PHARMACEUTICALS LLC $311.3706/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055094965 CMS
Kite Pharma, Inc. $5,020.0005/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270659 CMS
Kite Pharma, Inc. $35.1904/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270663 CMS
Kite Pharma, Inc. $49.9904/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270665 CMS
Kite Pharma, Inc. $49.9904/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270667 CMS
Kite Pharma, Inc. $303.9704/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270669 CMS
Kite Pharma, Inc. $448.2004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270671 CMS
Kite Pharma, Inc. $83.2102/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270661 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $50.0002/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993432421 CMS
Novartis Pharmaceuticals Corporation $58.1802/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992177973 CMS
Apellis Pharmaceuticals, Inc. $111.7202/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056314221 CMS
Apellis Pharmaceuticals, Inc. $13.1702/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056365761 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $2,700.0001/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993432423 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11,661.76 19
PY2020 $18,136.16 15
PY2021 $11,422.95 11
PY2022 $10,850.77 14
PY2023 $17,073.30 19
PY2024 $8,407.15 7
PY2025 $13,747.64 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $132,060.46 16
PY2024 Recipient $4,666.04 2
PY2024 Principal investigator $39,767.00 22
PY2023 Recipient $11,715.50 3
PY2023 Principal investigator $52,606.84 7
PY2022 Recipient $9,994.00 10
PY2022 Principal investigator $107,035.90 12
PY2021 Recipient $8,130.00 4
PY2021 Principal investigator $310,967.41 28
PY2020 Recipient $17,342.00 13
PY2020 Principal investigator $404,017.84 37
PY2019 Principal investigator $397,422.88 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient PFIZER INC. $940.00 12/08/2020 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742860273
Recipient PFIZER INC. $940.00 12/08/2020 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742860519
Principal investigator 1 PFIZER INC. $509.38 12/08/2020 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742900373
Principal investigator 1 PFIZER INC. $838.13 11/20/2020 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742930463
Principal investigator 1 Astellas Pharma Global Development $5,000.00 11/19/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
RANDOMIZED TRIAL OF GILTERITINIB VS MIDOSTAURIN IN FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML No dispute reported 06/30/2026 721323085
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $572.00 11/17/2020 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 737092453
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,244.10 11/09/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 737092189
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,748.00 10/26/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 737090977
Principal investigator 1 PFIZER INC. $10,082.51 10/21/2020 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742930467
Principal investigator 1 Celgene Corporation $244.44 10/19/2020 Non-covered Recipient Entity
Medical College Of Georgia
A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy & Safety Study of Fedratinib in Subjects w/ DIPSS-Intermediate or High-Risk PMF, post-PV MF, or post-ET MF & Previously Treated w/ Ruxolitinib incl. Sub-study w/ concomitant Luspatercept for anemia No dispute reported 06/30/2026 753808131
Principal investigator 1 PFIZER INC. $17,398.76 09/30/2020 Non-covered Recipient Entity
Augusta University AUMC
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742931877
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,403.62 09/29/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 737089503
Principal investigator 1 PFIZER INC. $21,219.40 09/17/2020 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742930527
Recipient Novartis Pharmaceuticals Corporation $2,500.00 09/16/2020 Covered Recipient Physician RESEARCH RELATED PUBLICATIONS SUPPORT No dispute reported 06/30/2026 721497865
Principal investigator 1 Incyte Corporation $275.34 08/10/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321077
Principal investigator 1 Incyte Corporation $30.40 08/10/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321079
Principal investigator 1 Incyte Corporation $80.20 08/10/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321081
Principal investigator 1 Incyte Corporation $66.85 08/10/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321083
Principal investigator 1 Incyte Corporation $23.40 08/10/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321085
Recipient PFIZER INC. $330.00 08/10/2020 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742860509
Recipient PFIZER INC. $330.00 08/10/2020 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742861691
Principal investigator 1 PFIZER INC. $70.00 07/27/2020 Non-covered Recipient Entity
Augusta University
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742880203
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $48,989.60 07/27/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 737085665
Recipient PFIZER INC. $780.00 07/15/2020 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742860511
Principal investigator 1 Incyte Corporation $3.04 07/09/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321087
Principal investigator 1 Incyte Corporation $5.44 07/09/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321089
Principal investigator 1 Incyte Corporation $36.29 07/09/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321091
Principal investigator 1 Incyte Corporation $31.91 07/09/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321093
Principal investigator 1 Incyte Corporation $2.19 07/09/2020 Non-covered Recipient Entity
GEORGIA CANCER CENTER
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321095
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,425.00 06/30/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 737084201
Principal investigator 1 PFIZER INC. $2,961.00 06/25/2020 Non-covered Recipient Entity
EMORY UNIVERSITY
A MULTICENTER PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 742886331
Recipient Novartis Pharmaceuticals Corporation $750.00 05/16/2020 Covered Recipient Physician RESEARCH RELATED PUBLICATIONS SUPPORT No dispute reported 06/30/2026 721497863
Recipient PFIZER INC. $780.00 05/14/2020 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742860515
Recipient Novartis Pharmaceuticals Corporation $655.00 05/05/2020 Covered Recipient Physician OUTCOMES RESEARCH No dispute reported 06/30/2026 721497859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $61,658.00 05/04/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 737078191
Recipient PFIZER INC. $3,200.00 04/28/2020 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742861695
Principal investigator 1 PFIZER INC. $4,935.00 04/28/2020 Non-covered Recipient Entity
EMORY UNIVERSITY
A MULTICENTER PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA No dispute reported 06/30/2026 742886529
Principal investigator 1 Astellas Pharma Global Development $2,476.00 04/24/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF THE FLT3 INHIBITOR GILTERITINIB ADMINISTERED AS MAINTENANCE THERAPY FOLLOWING ALLOGENEIC TRANSPLANT FOR PATIENTS WITH FLT3/ITD AML No dispute reported 06/30/2026 721321775
Principal investigator 1 Astellas Pharma Global Development $26,000.00 04/16/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
RANDOMIZED TRIAL OF GILTERITINIB VS MIDOSTAURIN IN FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML No dispute reported 06/30/2026 721321707
Principal investigator 1 PFIZER INC. $2,301.89 03/31/2020 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742952927
Principal investigator 1 PFIZER INC. $14,500.01 03/17/2020 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742952951
Recipient Novartis Pharmaceuticals Corporation $317.00 02/11/2020 Covered Recipient Physician RESEARCH RELATED PUBLICATIONS SUPPORT No dispute reported 06/30/2026 721497861
Recipient PFIZER INC. $3,200.00 02/10/2020 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742861689
Principal investigator 1 PFIZER INC. $52,196.28 02/10/2020 Non-covered Recipient Entity
Georgia Cancer Center Augusta University AUMC
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742952521
Principal investigator 1 PFIZER INC. $17,398.76 02/06/2020 Non-covered Recipient Entity
Georgia Cancer Center Augusta University AUMC
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742952743
Principal investigator 1 Astellas Pharma Global Development $4,650.00 01/31/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF THE FLT3 INHIBITOR GILTERITINIB ADMINISTERED AS MAINTENANCE THERAPY FOLLOWING ALLOGENEIC TRANSPLANT FOR PATIENTS WITH FLT3/ITD AML No dispute reported 06/30/2026 721321139
Principal investigator 1 PFIZER INC. $16,801.90 01/29/2020 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742952779
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,039.00 01/27/2020 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 737068473
Recipient Novartis Pharmaceuticals Corporation $2,620.00 01/21/2020 Covered Recipient Physician OUTCOMES RESEARCH No dispute reported 06/30/2026 721497857
Principal investigator 1 PFIZER INC. $18,800.00 01/21/2020 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT No dispute reported 06/30/2026 742952573